Advanced cancer treatment available through clinical trials
Deaconess is the only health care provider in the region to be a member of the National Cancer Institute’s National Community Oncology Research Program (NCORP) and approved to participate in the National Cancer Institute’s Molecular Analysis for Therapy Choice (NCI-MATCH) program. These designations provide Deaconess Cancer specialists with access to the world’s top 20+ cancer drugs in development today.
Clinical trials at Deaconess mean that our cancer specialists and their patients can be part of ground-breaking research and receive treatment options unavailable in our region. This includes exploration of precision medicine which targets a patient’s genetic changes found in the tumors.
Read below for more information about the clinical trials available. Certain criteria must be met for each trial so be sure to read the details.
- Trial code: NRG-BR003 - NCT02488967
- Trial code: SWOG S1418 - NCT02954874
- Trial code: CTSU S1207 - NCT01674140
- Trial code: ECOG-ACRIN EAY131 (MATCH) - NCT02465060